Apr 25, 2023 / 06:00PM GMT
Stephen Willey - Stifel Financial Corp. - Moderator
All right, thanks. Thanks, everyone for joining us here for the Virtual Oncology Day. I'm Stephen Willey, one of the senior analysts here at Stifel. And glad to have with us here for an afternoon session, Dr. John Scarlett from Geron. He's going to make a little bit of an opening statement and then, we're going to get right into Q&A. So Chief, I'm going to hand it over to you.
John Scarlett - Geron Corporation - President, CEO, Chairman
Yeah. Thanks a lot, Steve. Really appreciate being given the opportunity to speak, and I look forward to the coming discussion.
During the course of this fireside chat, there are going to be forward-looking statements regarding future events, performance plans, expectations, and other projections including those related to the therapeutic potential of and potential regulatory approval of imetelstat, anticipated clinical and commercial events and related timelines. Sufficiency of Geron's financial resources, and other statements that aren't historical fact and actual
Geron Corp at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 25, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers